Dr. Priya Kumthekar, Neuro-Oncology Section Editor for CANCER, and Dr. Helen Shih, Radiation Oncology Section Editor for CANCER, discuss the current treatment landscape for low-grade gliomas with a focus on the evolving role of isocitrate dehydrogenase (IDH) inhibitors. Drawing on findings from the INDIGO trial, they reflect on how recent evidence has informed ongoing discussions around the use of IDH inhibitors, alongside their perspectives on treatment planning and real-world clinical considerations. The conversation also emphasizes the importance of engaging patients in shared decision making throughout the course of care.
Drs. Kumthekar and Shih invite investigators in neuro-oncology, radiation oncology, and related disciplines to consider submitting their research to CANCER. Their closing remarks highlight the journal’s global reach, supportive editorial staff, and connection to the mission of the American Cancer Society.
Learn more about submitting your work to CANCER: https://acsjournals.onlinelibrary.wiley.com/journal/10970142/homepage/why-submit
Original music by J.Gilman.
Follow CANCER on social media:
x.com/JournalCancer
instagram.com/acsjournalcancer
linkedin.com/company/acs-journals
